🎉 Exciting news! The PCAN Journal has achieved a remarkable milestone with its new impact factor! 🌟 This is a testament to the hard work and dedication of our contributors, reviewers, and readers. Let's celebrate this achievement! 📚✨ #PCANImpactFactor #ResearchExcellence

#throwbackthursday 🩺💊 Alpha-blockers (ABs) for BPH: A BP-friendly choice?(june,2010) Our study on 2,924 men with BPH 📊 shows that ABs significantly reduce BP in hypertensive patients 📉, with doxazosin GITS offering optimal control! 🏥 No major BP changes in normotensive men. Safe & effective! ✅ 🔗 [ #BPH #Hypertension #Urology

🎙️ New Podcast Alert! 🚀 Don’t miss our exclusive 2025 interview with the Editor-in-Chief of Prostate Cancer and Prostatic Diseases! 🏥📖 Get insights into the future of prostate cancer research and what's next for the journal. 📺▶️ YouTube 🔗 | 🎧🎵 Spotify 🔗 #ProstateCancer #MedicalResearch #Podcast @cosimodenunzio

🩺🔬 Men with #BRCA1/2 variants had a 7.8x higher risk of #ProstateCancer than the general population! A low PSA threshold led to more diagnoses—but is biology also at play? 🤔 High recurrence rates raise concerns. More studies needed! 📢 👇 #CancerGenetics #MensHealth

RT @ggebraelmd: Just in @pcan_journal 👉 TP53, RB1, PTEN ➡️ worse PFS & OS in pts w/ mHSPC #prostatecancer treated w/ ADTi. After ext valida…

#throwbackthursday 📢 Is routine urine culture before prostate biopsy necessary? 🤔(April 2010) A study on 353 men found no difference in infection rates between those with and without pre-biopsy bacteriuria. Only 4 developed infections requiring antibiotics. 🔬 Key takeaway: Routine urine culture may not be needed if antibiotic prophylaxis & enema are used, except for those with a history of UTIs. 📖 Read more: [ #ProstateCancer #Urology #MensHealth

📢 New study on Active Surveillance & MRI in #ProstateCancer! 🔍 Men with negative MRI showed no need for treatment & no progression to high-grade cancer over time! 📉 PIRADS score strongly predicts risk—targeted biopsies may be enough! 🔗 Read more: [ #UroOncology #MRI

📢 New study on prostate cancer treatment! Patients with very high-risk prostate cancer benefit more from long-term androgen deprivation therapy (ltADT) than those with high-risk disease. However, no significant difference in treatment effect by risk group was found. Further research is needed! 🔬🩺 Read more here 👉 [ #ProstateCancer #Oncology #CancerResearch

🙌Throwback thursday🙌 📢 Inconsistent Reports on Long-Term PCa Treatment Complications! A review of 98 studies highlights the challenges in comparing risks of erectile dysfunction, urinary & bowel symptoms after RP, ERT/CRT & BRT. 📊 Standardized methods & broader risk assessments are needed! 🔍 Read more 👇👇👇 #ProstateCancer #Urology #Radiotherapy

Just landed on spotify! Keep update on the latest news on Prostate cancer and prostatic diseases! Listen to "First Episode: Prof.Elterman minimally invasive for BPH" by Prostate Cancer and Prostatic diseases Podcast. @DrDeanElterman @lucacindolo @cosimodenunzio @TDorffOnc @TimDaskivich

#ThrowbackThursday 📆 to the CMS price transparency rule (Jan 1, 2021). Our analysis shows 📊: 💰 Self-pay prices > insurance-negotiated 🏥 Academic & for-profit hospitals charge more 🤔 Local competition ≠ lower prices #ProstateCancer #HealthTransparency More here 👉

🧠 Smarter Prostate Surgery Decisions 🎯 Risk calculators now predict laterality of EPE for better surgical planning! 🔹 PSA density 🔹 PIRADS score 🔹 Gleason Grade 🔹 % Positivity of cores 📈 AUC up to 0.79! Explore it here: 🌐 #ProstateCancer #mpMRI #UrologyInnovation

"Well-deserved congratulations to Prof. Michele Marchioni for being named one of the top reviewers of 2024! Your commitment to advancing medical research is truly inspiring. 🌟📚 #TopReviewer #MedicalExcellence

"Congratulations to Dr Bauman Glenn, from Canada, for being recognized as one of the top reviewers for the journal in 2024! 🏆 Your commitment to advancing medical research is truly inspiring. 👏 #ExcellenceInReview #MedicalResearch"

"Congratulations to Prof. John Yaxley for being recognized as one of the top reviewers for the journal in 2024! 🏆 Your dedication and expertise continue to inspire the medical community. 👏 #ExcellenceInReview #MedicalResearch

"Congratulations to Dr. Celeste Manfredi for being recognized as one of the top reviewers of the journal in 2024! Your dedication and expertise make us proud. 👏📚 #ExcellenceInReview #TopReviewer2024

RT @brookmans76: Rethinking #ProstateBiopsy: ✅ A systematic review (23 studies, 12,324 pts) shows that #AntibioticProhylaxis can be omitt…

Same survival, less surgery! Intermediate-risk prostate cancer patients with negative PSMA PET showed no significant difference in BCR-free survival with or without PLND. 🏥👌 🔬 A step toward precision medicine! 🔗 Details:

RT @PrafulRavi1: Our latest #ICECAP work looking at whether clinical risk can identify benefit from short v long-term ADT in high-risk pros…